Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2009

View Archived Issues

CNTO-328-docetaxel combination active in metastatic castration-resistant prostate cancer

Disulfiram, a DNMT1 inhibitor with activity relevant to prostate cancer

Millennium initiates two phase II trials for Aurora A kinase inhibitor MLN-8237

Novexel's NXL-104/ceftazidime combination advances to phase II trials

Piramal completes acquisition of Minrad

Moberg Derma signs license and copromotion agreement for nail fungus drug K-101

Depomed completes enrollment in phase III clinical trial of DM-5689

Lab21 purchases majority shareholding in Biotec

Intellect Neurosciences' AD candidate Oxigon reported to have copper-binding properties

Chelsea announces results of phase II droxidopa study

Recent KuDOS and Cancer Research Technology patent describes novel DNA-PK inhibitors

New Met kinase inhibitors for cancer reported by Merck KGaA

Cediranib shows potential in docetaxel-resistant prostate cancer

RegeneRx completes enrollment and dosing in phase Ib clinical trial of RGN-352 in AMI

IDMC recommends continuation of clinical trial of Hana's Marqibo in ALL

Taisho scientists present new antidepressive NMU2 ligands

New peptides claimed by Les Biotechnologies Oceanova for dermatological disorders

Novel rivaroxaban prodrugs synthesized by Bayer researchers

FDA provides complete response to Erbitux head and neck cancer sBLA

Zonisamide reduces tremor scores in patients with essential tremor

Immatics completes recruitment in phase II IMA-901 trial in renal cell cancer

Anticonvulsants improve urodynamic parameters in rats with NDO

Astellas terminates ASP-2314/ACR-16 license agreement with Neurosearch

Zeria presents results from phase II Z-338 study in functional dyspepsia

Multiple Myeloma Research Foundation gives grants for two novel drug candidates

KV Pharmaceutical restructures company to focus on promotion of Acrux's Evamist